Restricted accessResearch articleFirst published online 2013-06
From Bench to Bedside: Preclinical Evaluation of a Self-Inactivating Gammaretroviral Vector for the Gene Therapy of X-linked Chronic Granulomatous Disease
Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by impaired antimicrobial activity in phagocytic cells. As a monogenic disease affecting the hematopoietic system, CGD is amenable to gene therapy. Indeed in a phase I/II clinical trial, we demonstrated a transient resolution of bacterial and fungal infections. However, the therapeutic benefit was compromised by the occurrence of clonal dominance and malignant transformation demanding alternative vectors with equal efficacy but safety-improved features. In this work we have developed and tested a self-inactivating (SIN) gammaretroviral vector (SINfes.gp91s) containing a codon-optimized transgene (gp91phox) under the transcriptional control of a myeloid promoter for the gene therapy of the X-linked form of CGD (X-CGD). Gene-corrected cells protected X-CGD mice from Aspergillus fumigatus challenge at low vector copy numbers. Moreover, the SINfes.gp91s vector generates substantial amounts of superoxide in human cells transplanted into immunodeficient mice. In vitro genotoxicity assays and longitudinal high-throughput integration site analysis in transplanted mice comprising primary and secondary animals for 11 months revealed a safe integration site profile with no signs of clonal dominance.
Stein and colleagues report on the comprehensive preclinical and safety studies that they conducted in order to transition a self-inactivating gammaretroviral vector into the clinic for use in subjects with X-linked chronic granulomatous disease. Their studies included assessment of dosage requirements, therapeutic efficacy, and resistance to transgene silencing and genotoxic potential.
Get full access to this article
View all access options for this article.
References
1.
AiutiA., BacchettaR., SegerR.et al.2012. Gene therapy for primary immunodeficiencies: part 2. Curr. Opin. Immunol., 24:585–591.
2.
Avedillo DiezI., ZychlinskiD., CociE.G.et al.2011. Development of novel efficient SIN vectors with improved safety features for Wiskott-Aldrich Syndrome stem cell based gene therapy. Mol. Pharmaceutics, 8:1525–1537.
3.
BaumC., Von KalleC., StaalF.J.et al.2004. Chance or necessity? Insertional mutagenesis in gene therapy and its consequences. Mol. Ther., 9:5–13.
4.
BaumC., ModlichU., GohringG.et al.2011. Concise review: managing genotoxicity in the therapeutic modification of stem cells. Stem Cells, 29:1479–1484.
5.
BiffiA., BartolomaeC.C., CesanaD.et al.2011. Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood, 117:5332–5339.
6.
BjorgvinsdottirH., DingC., PechN.et al.1997. Retroviral-mediated gene transfer of gp91phox into bone marrow cells rescues defect in host defense against Aspergillus fumigatus in murine X-linked chronic granulomatous disease. Blood, 89:41–48.
7.
BohlerM.C., SegerR.A., MouyR.et al.1986. A study of 25 patients with chronic granulomatous disease: a new classification by correlating respiratory burst, cytochrome b, and flavoprotein. J. Clin. Immunol., 6:136–145.
BrennerS., RyserM.F., ChoiU.et al.2006. Polyclonal long-term MFGS-gp91phox marking in rhesus macaques after nonmyeloablative transplantation with transduced autologous peripheral blood progenitor cells. Mol. Ther., 14:202–211.
10.
CartierN., Hacein-Bey-AbinaS., BartholomaeC.C.et al.2009. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science, 326:818–823.
11.
Cavazzana-CalvoM., PayenE., NegreO.et al.2010. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature, 467:318–322.
12.
Cavazzana-CalvoM., FischerA., Hacein-Bey-AbinaS.et al.2012. Gene therapy for primary immunodeficiencies: part 1. Curr. Opin. Immunol., 24:580–584.
13.
CornilsK., LangeC., SchambachA.et al.2009. Stem cell marking with promoter-deprived self-inactivating retroviral vectors does not lead to induced clonal imbalance. Mol. Ther., 17:131–143.
14.
CornilsK., BartholomaeC.C., ThieleckeL.et al.2012. Comparative clonal analysis of reconstitution kinetics after transplantation of hematopoietic stem cells gene marked with a lentiviral SIN or a gamma-retroviral LTR vector. Exp. Hematol., 41:28–38.e3.
15.
Corrigan-CurayJ., Cohen-HaguenauerO., O'reillyM.et al.2012. Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy. Mol. Ther., 20:1084–1094.
16.
DiW.L., SemenovaE., LarcherF.et al.2012. Human involucrin promoter mediates repression-resistant and compartment-specific LEKTI expression. Hum. Gene Ther., 23:83–90.
17.
DinauerM.C., CurnutteJ.T., RosenH.et al.1989. A missense mutation in the neutrophil cytochrome b heavy chain in cytochrome-positive X-linked chronic granulomatous disease. J. Clin. Invest., 84:2012–2016.
18.
DinauerM.C., GiffordM.A., PechN.et al.2001. Variable correction of host defense following gene transfer and bone marrow transplantation in murine X-linked chronic granulomatous disease. Blood, 97:3738–3745.
GerritsA., DykstraB., KalmykowaO.J.et al.2010. Cellular barcoding tool for clonal analysis in the hematopoietic system. Blood, 115:2610–2618.
21.
GlimmH., BallC.R., Von KalleC.2011. You can count on this: barcoded hematopoietic stem cells. Cell Stem Cell, 9:390–392.
22.
GoebelW.S., MarkL.A., BillingsS.D.et al.2005. Gene correction reduces cutaneous inflammation and granuloma formation in murine X-linked chronic granulomatous disease. J. Invest. Dermatol., 125:705–710.
23.
GrezM., ReichenbachJ., SchwäbleJ.et al.2011. Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol. Ther., 19:28–35.
24.
Hacein-Bey-AbinaS., GarrigueA., WangG.P.et al.2008. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest., 118:3132–3142.
HoweS.J., MansourM.R., SchwarzwaelderK.et al.2008. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest., 118:3143–3150.
27.
HuhnR.D., TisdaleJ.F., AgricolaB.et al.1999. Retroviral marking and transplantation of rhesus hematopoietic cells by nonmyeloablative conditioning. Hum. Gene Ther., 10:1783–1790.
28.
HustonM.W., Van TilN.P., VisserT.P.et al.2011. Correction of murine SCID-X1 by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning. Mol. Ther., 19:1867–1877.
29.
KahlC.A., TarantalA.F., LeeC.I.et al.2006. Effects of busulfan dose escalation on engraftment of infant rhesus monkey hematopoietic stem cells after gene marking by a lentiviral vector. Exp. Hematol., 34:369–381.
30.
KangE.M., HsiehM.M., MetzgerM.et al.2006. Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model. Exp. Hematol., 34:132–139.
31.
KuhnsD.B., AlvordW.G., HellerT.et al.2010. Residual NADPH oxidase and survival in chronic granulomatous disease. NEJM, 363:2600–2610.
32.
LoewR., MeyerY., KuehlckeK.et al.2010. A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating gamma-retroviral vectors using targeted integration. Gene Ther., 17:272–280.
33.
LuR., NeffN.F., QuakeS.R.et al.2011. Tracking single hematopoietic stem cells in vivo using high-throughput sequencing in conjunction with viral genetic barcoding. Nat. Biotechnol., 29:928–933.
34.
ModlichU., BohneJ., SchmidtM.et al.2006. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity. Blood, 108:2545–2553.
35.
ModlichU., SchambachA., BrugmanM.H.et al.2008. Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16. Leukemia, 22:1519–1528.
36.
ModlichU., NavarroS., ZychlinskiD.et al.2009. Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol. Ther., 17:1919–1928.
37.
MontiniE., CesanaD., SchmidtM.et al.2006. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat. Biotechnol., 24:687–696.
38.
MontiniE., CesanaD., SchmidtM.et al.2009. The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. J. Clin. Invest., 119:964–975.
39.
Moreno-CarranzaB., GentschM., SteinS.et al.2009. Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells. Gene Ther., 16:111–118.
40.
NaldiniL.2011. Ex vivo gene transfer and correction for cell-based therapies. Nat. Rev. Genet., 12:301–315.
41.
OttM.G., SchmidtM., SchwarzwaelderK.et al.2006. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat. Med., 12:401–409.
42.
PetersenJ.E., HiranT.S., GoebelW.S.et al.2002. Enhanced cutaneous inflammatory reactions to Aspergillus fumigatus in a murine model of chronic granulomatous disease. J. Invest. Dermatol., 118:424–429.
RosenzweigM., MacvittieT.J., HarperD.et al.1999. Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates after nonablative conditioning. Blood, 94:2271–2286.
45.
SadatM.A., DirscherlS., SastryL.et al.2009. Retroviral vector integration in post-transplant hematopoiesis in mice conditioned with either submyeloablative or ablative irradiation. Gene Ther., 16:1452–1464.
46.
ScaramuzzaS., BiascoL., RipamontiA.et al.2013. Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome. Mol. Ther., 21:175–184.
47.
SchambachA., BohneJ., ChandraS.et al.2006. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. Mol. Ther., 13:391–400.
48.
SchambachA., SwaneyW.P., Van Der LooJ.C.2009. Design and production of retro- and lentiviral vectors for gene expression in hematopoietic cells. Methods Mol. Biol., 506:191–205.
49.
SchmidtM., SchwarzwaelderK., BartholomaeC.et al.2007. High-resolution insertion-site analysis by linear amplification-mediated PCR (LAM-PCR)Nat. Methods, 4:1051–1057.
50.
SegalA.W.1996. The NADPH oxidase and chronic granulomatous disease. Mol. Med. Today, 2:129–135.
51.
SegalB.H., LetoT.L., GallinJ.I.et al.2000. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore), 79:170–200.
52.
SeymourL.W., ThrasherA.J.2012. Gene therapy matures in the clinic. Nat. Biotechnol., 30:588–593.
53.
ShannonC.E.1948. A mathematical theory of communication. Bell Syst. Tech. J., 27:379–423and 623–656.
54.
SimpsonE.H.1949. Measurement of diversity. Nature, 163:688.
55.
SteinS., OttM.G., Schultze-StrasserS.et al.2010. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat. Med., 16:198–204.
56.
ThornhillS.I., SchambachA., HoweS.J.et al.2008. Self-inactivating gammaretroviral vectors for gene therapy of X-linked severe combined immunodeficiency. Mol. Ther., 16:590–598.
57.
TolarJ., BeckerP.S., ClappD.W.et al.2012. Gene therapy for fanconi anemia: one step closer to the clinic. Hum. Gene Ther., 23:141–144.
58.
WillE., BaileyJ., SchueslerT.et al.2007. Importance of murine study design for testing toxicity of retroviral vectors in support of phase I trials. Mol. Ther., 15:782–791.
59.
ZhangC.C., KabaM., GeG.et al.2006. Angiopoietin-like proteins stimulate ex vivo expansion of hematopoietic stem cells. Nat. Med., 12:240–245.
60.
ZhouS., ModyD., DeravinS.S.et al.2010. A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells. Blood, 116:900–908.
61.
ZychlinskiD., SchambachA., ModlichU.et al.2008. Physiological promoters reduce the genotoxic risk of integrating gene vectors. Mol. Ther., 16:718–725.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
